Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.

PACBNYSE / NASDAQHealthcareSmall cap

$1.63-$0.13 (-7.4%)

Last close · Data as of Nov 20, 2026

Market cap
$506.3M
P/E
-0.9x
EV / EBITDA
-7.5x
Revenue
$160.0M
Net margin
-341.5%
ROCE
-78.4%

-13.3% over the last year

Pacific Biosciences of California, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-16.8%
3M
+32.5%
6M
+37.0%
1Y
-13.3%
5Y
Hidden
  • This period includes a one-day price step on 16 Apr 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.13 (-7.4%) from $1.76 to $1.63 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PACB, bought on each weekday since 2021.

News & filings

What Pacific Biosciences of California filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 546 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 5.15 times current liabilities.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.

Read moreShow less

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Sector
Healthcare
Shares outstanding
302.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$506.3M
P/E
-0.9x
P/B
94.6x
EV / EBITDA
-7.5x
EV / Sales
7.2x
P/S
3.2x
52-week high
$2.90
52-week low
$1.11

Profitability

Operating margin
-348.5%
Net margin
-341.5%
EBITDA margin
-95.4%
ROE
-10214.5%
ROCE
-78.4%
ROIC
-66.1%
ROA
-69.7%
Asset turnover
0.20

Growth

Revenue
$160.0M
Revenue growth, 1Y
3.9%
Revenue CAGR, 3Y
7.6%
Net profit growth, 1Y
76.3%
Free cash flow
-$118.9M

Solvency

Current ratio
5.15
Debt / Equity
131.32
Debt / Assets
0.90
CFO / Net profit
0.20
Cash / Market cap
12.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$160.0M
Cost of revenue$114.2M
Gross profit$45.8M
Operating expenses$603.3M
Research and development$97.3M
Selling, general and administrative$141.5M
Operating income-$557.6M
Interest and other$11.5M
Pretax income-$546.1M
Tax and other$320.0k
Net income-$546.4M

Revenue and net profit

Revenue grew 3.9% in FY2025; net profit is the dashed line.

Pacific Biosciences of California, Inc. revenue and net profit by fiscal year
Pacific Biosciences of California, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$128.3M-$314.2M
FY2023$200.5M-$306.7M
FY2024$154.0M-$309.9M
FY2025$160.0M-$546.4M

Cash flows

FY2025: -$111.2M from operations, -$118.9M free after investment (dashed).

Pacific Biosciences of California, Inc. operating and free cash flow by fiscal year
Pacific Biosciences of California, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$263.2M-$280.1M
FY2023-$259.2M-$268.0M
FY2024-$206.1M-$212.2M
FY2025-$111.2M-$118.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$160.0M+3.9%1Y
EBITDA
-$152.7M
Net profit
-$546.4M
Cash from operations
-$111.2M
Free cash flow
-$118.9M
Revenue CAGR, 3Y
7.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$160.0M-$152.7M-$546.4M-$118.9M-10214.5%+3.9%+76.3%

Monthly returns

Month-by-month returns of PACB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$784.1M
Liabilities$778.7M
Equity$5.3M
Paid-in capital$2.7B
Retained earnings-$2.7B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PACB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Pacific Biosciences of California, Inc. (this company)7.2x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Pacific Biosciences of California, Inc.PACBthis company$506.3M-0.9x94.6x-10214.5%-7.5x
XOMA Royalty CorporationXOMA$531.7M16.8x6.3x37.8%12.1x
4D Molecular Therapeutics, Inc.FDMT$523.3M-3.7x1.0x-27.7%-3.2x
Aquestive Therapeutics, Inc.AQST$519.4M-6.2x-15.4x248.9%-6.7x
Arvinas, Inc.ARVN$499.4M-6.2x1.2x-18.6%-3.2x
AngioDynamics, Inc.ANGO$497.1M-14.6x2.7x-18.6%256.3x
Standard BioTools Inc.LAB$495.8M-6.6x1.2x-17.7%-4.7x
Evolent Health, Inc.EVH$492.7M-0.9x1.2x-128.7%-3.7x
Prothena Corporation plcPRTA$484.3M-2.0x1.7x-87.0%-1.0x
Peer median—-5.0x1.2x-18.6%-3.2x

Year-to-date ROI

PACB since 1 January, against earlier years.

Historical volatility

PACB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Pacific Biosciences of California, Inc. operating margin by fiscal year
Pacific Biosciences of California, Inc. operating margin by fiscal year
DateOperating margin
FY2022-237.6%
FY2023-154.8%
FY2024-188.7%
FY2025-348.5%
LineFY2025
Cost of revenueCost Of Revenue$114.2M
Gross profitGross Profit$45.8M
Operating expensesOperating Expense$603.3M
Research and developmentResearch And Development$97.3M
Selling, general and administrativeSelling General And Administration$141.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$364.5M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$364.5M
Amortization$364.5M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$364.5M
Total expensesTotal Expenses$717.6M
Pretax incomePretax Income-$546.1M

Learn while you research

Academy chapters picked for Pacific Biosciences of California, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 131.32 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →